News

Amarin, an Ireland-based clinical-stage biopharmaceutical company, has reached an agreement with the FDA under a special protocol assessment for its planned Phase III registration clinical trial of AMR101

First quarter 2009 product revenues consisted of $1.3 million in Celution System sales in Europe and Asia and the recognition of $0.6 million from the installation of a

Revenues for the nine months ended March 31, 2009 were $29.3 million, a $1.3 million decrease against revenues of $30.6 million for the nine months ended March 31,

Biovail Corporation has reported that its subsidiary Biovail Laboratories International has entered into an agreement to acquire full US commercialization rights to Wellbutrin XL tablets from GlaxoSmithKline. Under

Instrumentation Laboratory, a developer and manufacturer of diagnostic medical equipment, has received the FDA’s 510(k) clearance for the ACL AcuStar hemostasis testing system. This clearance allows Instrumentation Laboratory

Potentia Pharmaceuticals, a biotechnology company, has successfully completed its Phase I ASaP clinical trial for POT-4, the company’s lead drug candidate for the treatment of age-related macular degeneration.

LifeCycle Pharma, a specialty pharmaceutical company, has reported positive interim results from a Phase II clinical trial involving 63 patients comparing LCP-Tacro tablets administered once daily versus Prograf

Lux Biosciences, a biotechnology company, has reported positive results from an international Phase III program in uveitis, the Luminate trials, which demonstrated the ability of LX211 to significantly

Novartis has reported that Glivec has received approval from the European Commission to become the first and only treatment available in Europe to reduce the risk of recurrence